UNITUXIN

PeakmAb

dinutuximab

BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

Glycolipid Disialoganglioside-directed Antibody Interactions

Pharmacologic Class:

Glycolipid Disialoganglioside-directed Antibody

Clinical Trials (5)

NCT07261241Phase 2Not Yet Recruiting

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

Started Jul 2026
118 enrolled
Neuroblastoma
NCT05421897Phase 1Active Not Recruiting

Rapid Administration Pilot for Infusing Dinutuximab

Started Nov 2022
11 enrolled
Neuroblastoma
NCT05080790Phase 2Completed

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Started Nov 2021
7 enrolled
Leiomyosarcoma
NCT04253015N/ARecruiting

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Started Sep 2019
125 enrolled
Neuroblastoma
NCT03332667Phase 1Completed

MIBG With Dinutuximab +/- Vorinostat

Started Sep 2018
45 enrolled
Neuroblastoma